Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
OMER
OMER
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
OMER News
Omeros Corporation Begins First Shipments of Yartemlea Therapy
Jan 27 2026
seekingalpha
iShares U.S. Pharmaceuticals ETF Declines 1.8% on Thursday
Jan 15 2026
NASDAQ.COM
ALX Oncology Gains 10.17% on Positive Phase 2 Trial Data for Evorpacept
Jan 08 2026
NASDAQ.COM
IHE ETF Shows 9.94% Upside Potential Based on Analyst Targets
Jan 05 2026
NASDAQ.COM
Biotech Stocks Surge at Year-End 2025, ETFs Gain 35.84%
Dec 31 2025
Benzinga
Omeros Corp Offers 26.6% Annualized Return on $10 Strike Put Options
Dec 29 2025
NASDAQ.COM
Omeros Announces FDA Approval of YARTEMLEA and Conference Call on January 7, 2026
Dec 27 2025
Newsfilter
Omeros Corporation Schedules Conference Call for FDA Approval of YARTEMLEA on January 7, 2026
Dec 26 2025
Businesswire
Galectin Secures $10M Credit Line, FDA Provides Guidance on Regulatory Pathway
Dec 26 2025
NASDAQ.COM
Biohaven Ltd's Depression Drug Trial Fails to Meet Primary Endpoint, Shares Plunge 14.3%
Dec 26 2025
Benzinga
Omeros Receives FDA Approval for YARTEMLEA to Treat TA-TMA
Dec 26 2025
Newsfilter
Davis Commodities Reports $95M Revenue in H1, Up 42.1%
Dec 26 2025
Benzinga
Omeros (OMER) Receives Buy Rating with 123.86% Price Target Upside
Dec 25 2025
NASDAQ.COM
Nike CEO Tim Cook Buys 50,000 Shares, Stock Rises 4.64%
Dec 25 2025
Benzinga
Omeros Secures FDA Approval for First TA-TMA Treatment, Shares Surge 76%
Dec 24 2025
Fool
Omeros Secures FDA Approval for First TA-TMA Treatment
Dec 24 2025
NASDAQ.COM
Show More News
